Patent intelligence · US
US 10519186
Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus
Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus
Patent details — US 10519186
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 31, 2019
- Expiration
- Dec 26, 2039
- Applicant
- Atea Pharmaceuticals, Inc.
- Claims
- 52
- CPC classes
- A61K, A61K31/7076, A61K31/708, A61K45/06
Quick answer
US 10519186 (Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus) is held by Atea Pharmaceuticals, Inc.. Status: granted. Granted Dec 31, 2019. Expires Dec 26, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Atea Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 52
- CPC classes
- A61K, A61K31/7076, A61K31/708, A61K45/06, A61K9/20, A61K9/2054
More from Atea Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12226429
Highly active compounds against COVID-19
granted -
US 12084473
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
granted -
US 12006340
Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
granted -
US 12005139
Ophthalmic formulations and related methods
granted -
US 11975016
2′-substituted-N6-substituted purine nucleotides for RNA virus treatment
granted -
US 11964047
Ophthalmic formulations and related methods
granted -
US 11833160
Ursodeoxycholic acid derivatives as HDAC inhibitors for the treatment of polycystic diseases
granted -
US 11813278
Highly active compounds against COVID-19
granted
Frequently asked questions
What is US patent 10519186?
US 10519186 (Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus) is held by Atea Pharmaceuticals, Inc.. Status: granted. Granted Dec 31, 2019. Expires Dec 26, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10519186?
Atea Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 35 pharmaceutical patents for this assignee.
When does US 10519186 expire?
Our index shows an expiration date of Dec 26, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.